Technical Data
Interferon beta 1 (beta 1b), Recombinant, Human (IFNb1, IFNb1b)
Molecular Biology Storage: -20CShipping: RT
One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity. The synthesis of IFN-beta can be induced by common inducers of interferons, including viruses, double-stranded RNA, and micro-organisms. It is induced also by some cytokines such as TNF and IL-1.

Recombinant Human IFN-beta 1b is a single, non-glycosylated mutein (variant form) of human Interferon beta-1b polypeptide chain containing 165 amino acids and having a molecular mass of 18.5kD. The Interferon beta gene was cloned from human fibroblasts and altered to substitute Serine for the Cysteine residue found at position 17.

Amino Acid Sequence:
The sequence of the first five N-terminal amino acids was determined and was found to be Ser-Tyr-Asn-Leu-Leu.

Biological Activity:
Interferon beta-1b is fully biologically active when compared to standard. The specific activity as determined in a viral resistance assay (human "Wish" cell line and VSV virus or the monkey VERO cell line with EMCV virus) was found to be 32x10e6IU/mg.

Protein Content:
Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280nm using the absorbency value of 1.493 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics).
2. Analysis by RP-HPLC, using a calibrated solution of IFN-beta as a Reference Standard.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months after receipt at -20C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
Source: E. coli
Purity: 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.
Concentration: ~0.1mg/ml
Form: Supplied as a lyophilized powder containing 50mg/ml HSA, 50mg/ml dextrose. Reconstitute with sterile ddH2O to a concentration >0.1mg/ml

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. Bitsch A, Dressel A, Bogumil T, Poser S, J Neurol 2004 Dec;251(12):1498-1501 2. Cost-utility of interferon beta(1b) in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. Kobelt G, Jonsson L, Eur J Health Econ 2003 Mar;4(1):50-9 3. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis. Deisenhammer F, Giovannoni G, Mult Scler 2004 Dec;10(6):713-4; author reply 715 4. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Panitch H, Miller A, Weinshenker B, Neurology 2004 Nov 23;63(10):1788-95 5. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Kappos L, Weinshenker B, Thompson AJ, McFarland H, Neurology 2004 Nov 23;63(10):1779-87 6. Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis. Bitsch A, Bahner D, Elitok E, Tumani H, Acta Neurol Scand 2004 Dec;110(6):386-92.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.